Literature DB >> 12667207

Transmembrane T-cell receptor peptides inhibit B- and natural killer-cell function.

Nghi T Huynh1, Rosemary A Ffrench, Ross A Boadle, Nicholas Manolios.   

Abstract

A synthetic hydrophobic peptide (core peptide; CP) containing two positively charged amino acids, lysine and arginine was derived from the transmembrane sequence of the T-cell receptor (TCR) alpha chain and has been shown to inhibit T-cell-mediated inflammation. In this study, we investigated the specificity of CP (10 microm) on lymphocyte function and found that it significantly inhibited interleukin-2 production in T cells and natural killer cytotoxicity by 46-58% compared to positive control. CP had no effects on B-cell proliferative responses when used at these concentrations; however, it suppressed B-cell proliferation at higher concentrations (50 microm). Inhibition by CP was not the result of membrane pore formation or cytotoxicity when examined by trypan blue, propidium iodide staining or transmission electron microscopy. CP analogues, with both lysine and arginine replaced by neutral or negatively charged amino acids, or by randomly distributing charges in the peptide sequence, had no effect on lymphocyte function. These results suggest that peptide inhibition is affected by its structure and charge interactions, and may involve common signalling molecules in T, B and natural killer cells. The potential of the immuno-inhibitory effects of CP as a novel anti-inflammatory peptide in therapy should be further explored.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667207      PMCID: PMC1782915          DOI: 10.1046/j.1365-2567.2003.01614.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

Review 1.  The structure, dynamics and orientation of antimicrobial peptides in membranes by multidimensional solid-state NMR spectroscopy.

Authors:  B Bechinger
Journal:  Biochim Biophys Acta       Date:  1999-12-15

Review 2.  Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes.

Authors:  K Matsuzaki
Journal:  Biochim Biophys Acta       Date:  1999-12-15

Review 3.  Amphipathic, alpha-helical antimicrobial peptides.

Authors:  A Tossi; L Sandri; A Giangaspero
Journal:  Biopolymers       Date:  2000       Impact factor: 2.505

4.  Signaling via LAT (linker for T-cell activation) and Syk/ZAP70 is required for ERK activation and NFAT transcriptional activation following CD2 stimulation.

Authors:  M P Martelli; H Lin; W Zhang; L E Samelson; B E Bierer
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

5.  Therapeutic application of T cell receptor mimic peptides or cDNA in the treatment of T cell-mediated skin diseases.

Authors:  G P Göllner; G Müller; R Alt; J Knop; A H Enk
Journal:  Gene Ther       Date:  2000-06       Impact factor: 5.250

6.  Human natural killer (NK) cells present staphylococcal enterotoxin B (SEB) to T lymphocytes.

Authors:  J A D'Orazio; J Stein-Streilein
Journal:  Clin Exp Immunol       Date:  1996-05       Impact factor: 4.330

Review 7.  Regulation of CD40 ligand expression and use of recombinant CD40 ligand for studying B cell growth and differentiation.

Authors:  M R Kehry; B E Castle
Journal:  Semin Immunol       Date:  1994-10       Impact factor: 11.130

8.  The T cell antigen receptor alpha and beta chains interact via distinct regions with CD3 chains.

Authors:  N Manolios; O Kemp; Z G Li
Journal:  Eur J Immunol       Date:  1994-01       Impact factor: 5.532

9.  Association of a 70-kDa tyrosine phosphoprotein with the CD16: zeta: gamma complex expressed in human natural killer cells.

Authors:  E Vivier; A J da Silva; M Ackerly; H Levine; C E Rudd; P Anderson
Journal:  Eur J Immunol       Date:  1993-08       Impact factor: 5.532

10.  The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions.

Authors:  R Biassoni; C Cantoni; M Falco; S Verdiani; C Bottino; M Vitale; R Conte; A Poggi; A Moretta; L Moretta
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

View more
  10 in total

Review 1.  New therapeutic strategies targeting transmembrane signal transduction in the immune system.

Authors:  Alexander B Sigalov
Journal:  Cell Adh Migr       Date:  2010-04-24       Impact factor: 3.405

2.  Gene therapy in diabetes.

Authors:  Mary S Wong; Wayne J Hawthorne; Nicholas Manolios
Journal:  Self Nonself       Date:  2010-06-09

3.  The SCHOOL of nature: III. From mechanistic understanding to novel therapies.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-06-11

4.  The SCHOOL of nature: IV. Learning from viruses.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-10

Review 5.  T-cell antigen receptor (TCR) transmembrane peptides: A new paradigm for the treatment of autoimmune diseases.

Authors:  Nicholas Manolios; Marina Ali; Vera Bender
Journal:  Cell Adh Migr       Date:  2010-04-30       Impact factor: 3.405

Review 6.  Membrane receptor activation mechanisms and transmembrane peptide tools to elucidate them.

Authors:  Justin M Westerfield; Francisco N Barrera
Journal:  J Biol Chem       Date:  2019-12-25       Impact factor: 5.157

Review 7.  Drugging Membrane Protein Interactions.

Authors:  Hang Yin; Aaron D Flynn
Journal:  Annu Rev Biomed Eng       Date:  2016-02-05       Impact factor: 9.590

Review 8.  Targeting Intramembrane Protein-Protein Interactions: Novel Therapeutic Strategy of Millions Years Old.

Authors:  Alexander B Sigalov
Journal:  Adv Protein Chem Struct Biol       Date:  2017-07-24       Impact factor: 3.507

Review 9.  Viral pathogenesis, modulation of immune receptor signaling and treatment.

Authors:  Walter M Kim; Alexander B Sigalov
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 10.  SCHOOL model and new targeting strategies.

Authors:  Alexander B Sigalov
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.